Oct. 11 Company Quick Takes: FDA approves Lilly migraine drug; plus Clovis, Evotec-Celmatix, Avacta-ADC and Neumentum-J&J

FDA approves Lilly’s Reyvow for migraine
FDA approved Reyvow lasmiditan from Eli Lilly and Co. (NYSE:LLY) to treat acute migraine with or without aura. It is the first agonist of serotonin (5-HT1F) approved for the indication. Lilly regained lasmiditan in 2017 through its $960 million acquisition of CoLucid Pharmaceuticals Inc. (see "Lilly's Lasmiditan Passes Second Phase III Test").

Rubraca available on England’s Cancer Drugs Fund
U.K.’s NICE has recommended use of Rubraca rucaparib from Clovis Oncology Inc. (NASDAQ:CLVS) for women with relapsed ovarian cancer through the Cancer Development Fund. ...